[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients included in the study will be examined by FIS; A-PASC; AQoL; PHQ; GAD-7; and Clinical Global Impression (CGI) questionnaires to determine neuropsychiatric symptoms and the current symptom severity at study entry; at initiation; during (after 2 weeks); at the end of 4 weeks of tDCS treatment and with an interval of 4 weeks after. Attention-oriented cognitive tests (computer variant) (Digit Span - forward span); working memory (Digit Span - backwards span) and psychomotor tempo (Digit Symbol Substitution Test) will be performed at the beginning and subsequent follow-ups. In addition; three EEG examinations will be performed during the study (before the start of tDCS; after two weeks of tDCS; and at the end of tDCS treatment). Patients will be randomly allocated according to permuted block design to one of two intervention groups: active anodal tDCS or placebo anodal tDCS. Each tDCS session (active or placebo) will last 30 minutes. A total of 20 tDCS sessions will be administered to patients over four weeks. The HDCStim programmable stimulator (Newronika; Italy) available for a double-blind design will be used for the application of tDCS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2484, "treatment_name": "Anodal tdcs", "treatment_type": "Rehabilitation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]